(Q35687692)

9 August 2017

1 reference

title

Antiangiogenic strategies, compounds, and early clinical results in breast cancer (English)

1 reference

9 August 2017

main subject

angiogenesis inhibitor

1 reference

1

Alessandro Morabito

1 reference

9 August 2017

Roberta Sarmiento

2

1 reference

9 August 2017

Paola Bonginelli

series ordinal

3

1 reference

9 August 2017

Giampietro Gasparini

series ordinal

4

1 reference

9 August 2017

publication date

1 February 2004

1 reference

Critical Reviews in Oncology Hematology

9 August 2017

published in

1 reference

9 August 2017

volume

49

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

91-107

1 reference

Tumor angiogenesis: therapeutic implications

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Signaling vascular morphogenesis and maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Mechanisms of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Isolation of putative progenitor endothelial cells for angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

A role for hematopoietic stem cells in promoting angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Genes expressed in human tumor endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Role of integrins in angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Isolation of a tumor factor responsible for angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Association of Angiogenesis in Lymph Node Metastases With Outcome of Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Angiogenesis as a marker of preneoplastic lesions of the human breast

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Vascular endothelial growth factor (VEGF) and its receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Angiogenic response of MCF7 human breast cancer to hormonal treatment: assessment by dynamic GdDTPA-enhanced MRI at high spatial resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Clinical significance of determination of surrogate markers of angiogenesis in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

VEGF-D promotes the metastatic spread of tumor cells via the lymphatics

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

From angiogenesis to lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Prognostic value of vascular endothelial growth factor in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Expression of vascular endothelial growth factor (VEGF) family members in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Combined effects of angiostatin and ionizing radiation in antitumour therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Mechanisms and future directions for angiogenesis-based cancer therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

The rationale and future potential of angiogenesis inhibitors in neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Matrix metalloproteinases: biologic activity and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Metronomic scheduling: the future of chemotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Inhibitory effect of full-length human endostatin on in vitro angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Phase I study of recombinant human endostatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Development of matrix metalloproteinase inhibitors in cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Target molecules for anti-angiogenic therapy: from basic research to clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Matrix metalloproteinase inhibition: a review of anti-tumour activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Metalloproteinases: role in breast carcinogenesis, invasion and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Marimastat (BB2516): current status of development

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Marimastat: the clinical development of a matrix metalloproteinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Marimastat in patients with advanced pancreatic cancer: a dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Inhibition of Angiogenesis and Murine Hemangioma Growth by Batimastat, a Synthetic Inhibitor of Matrix Metalloproteinases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Angiozyme: a novel angiogenesis inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Suramin: an anticancer drug with a unique mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Definition of Two Angiogenic Pathways by Distinct alpha(v) Integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

THALIDOMIDE AND CONGENITAL ABNORMALITIES

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Thalidomide in solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Thalidomide for the treatment of patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Thalidomide in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Phase II evaluation of thalidomide in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Differential immunohistochemical detection of transforming growth factor α, amphiregulin and CRIPTO in human normal and malignant breast tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

The role of EGFR-directed therapy in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Nature of interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(Carbonyl-bis[imino-N-methyl-4, 2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino] )bis-(1, 3-naphthalene disulfonate).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Anti-insulin-like growth factor-I activity of a novel polysulphonated distamycin A derivative in human lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Regulation of the immune response by prostaglandins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Rapid and transient induction of cyclo-oxygenase 2 by epidermal growth factor in human amnion-derived WISH cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Regulation of cyclooxygenase-2 pathway by HER2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Hypoxic induction of interleukin-8 gene expression in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Celecoxib: a specific COX-2 inhibitor with anticancer properties

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Effects of AGM-1470 and pentosan polysulphate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Clinical translation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900168-9

7 January 2021

10.1016/S1040-8428(03)00168-9

Identifiers

DOI

1 reference

9 August 2017

1 reference